Pacific Biosciences of California, Inc. (PACB)
Valuation Overview•Is Pacific Biosciences of California, Inc. Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
Fragile underlying quality score of 27/100; weak margins or elevated debt leverage warrant caution.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street is cautious, forecasting potential downside with steady expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
PACB struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company demonstrates solid revenue growth (7.6% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-101.7%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $37.2M | +3.9% | +7.6% | +15.2% | +5.6% | |
| EBITDA | -$37.9M | — | +43.4% | — | — | |
| Net Income | -$8.3M | -76.3% | -20.2% | — | -32.9% | |
| EPS (Diluted) | $-0.03 | -70.1% | — | — | -15.8% | |
| Free Cash Flow | -$47.7M | +46.3% | +25.9% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 37.1% | 27.4% | 33.1% | 36.3% |
| Operating Margin | -101.7% | -274.4% | -244.8% | -177.0% |
| Net Margin | -80.3% | -231.9% | -215.9% | -144.6% |
| FCF Margin | -72.6% | -115.4% | -130.9% | -97.4% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.17 | $-0.12 | +29.4% | ||
| Q1'26 | $-0.19 | $-0.12 | +36.8% | ||
| Q4'25 | $-0.16 | $-0.12 | +25.0% | ||
| Q3'25 | $-0.18 | $-0.13 | +27.8% | ||
| Q2'25 | $-0.19 | $-0.15 | +21.1% | ||
| Q1'25 | $-0.20 | $-0.20 | +0.0% | ||
| Q4'24 | $-0.22 | $-0.22 | +0.0% | ||
| Q3'24 | $-0.24 | $-0.20 | +16.7% |
Total return is +6.9% (1Y), lagging the benchmark by -18.1%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -23.9% | -33.2% | — |
| 1Y | +6.9% | -18.1% | — |
| 3YCAGR | -52.6% | -72.8% | — |
| 5YCAGR | -45.5% | -58.6% | — |
| 10YCAGR | -16.9% | -30.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Pacific Biosciences of California, Inc. (PACB) valuation, health, and returns.
Pacific Biosciences of California, Inc. valuation is being assessed using available models.
Pacific Biosciences of California, Inc. has multiple valuation anchors: Wall Street Analyst Target: $1.00 (implying -28.6% upside). A convergence of these signals offers higher conviction.
Pacific Biosciences of California, Inc. displays weak financial health with a composite quality score of 27/100, supported by a Altman Z-Score of -7.2 (distress zone), Piotroski F-Score of 3/9, Return on Invested Capital (ROIC) of -45.8%.
Pacific Biosciences of California, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Pacific Biosciences of California, Inc.'s current growth trajectory is Decelerating. The company achieved +3.9% 1Y revenue growth and -70.1% 1Y EPS growth, compared to its 3Y revenue CAGR of +7.6%.
Wall Street consensus is Buy based on 18 analysts, beating EPS expectations in 67% of recent quarters with a 5-quarter streak. The consensus price target represents a -28.6% change from current levels.
Investment risks for Pacific Biosciences of California, Inc. include: -58.1% 1-year max drawdown, high beta (2.60x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 2.60x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.